BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 8787218)

  • 21. Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis.
    Rothstein JD
    Adv Neurol; 1995; 68():7-20; discussion 21-7. PubMed ID: 8787245
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The urokinase system of plasminogen activator plays a role in amyotrophic lateral sclerosis (ALS) pathogenesis.
    Beal MF
    Exp Neurol; 2008 Jun; 211(2):332-3. PubMed ID: 18423450
    [No Abstract]   [Full Text] [Related]  

  • 23. Neurodegenerative disease. Guam's deadly stalker: on the loose worldwide?
    Miller G
    Science; 2006 Jul; 313(5786):428-31. PubMed ID: 16873621
    [No Abstract]   [Full Text] [Related]  

  • 24. Neurotrophic factors as therapeutic agents in amyotrophic lateral sclerosis. Potential and pitfalls.
    Henderson CE
    Adv Neurol; 1995; 68():235-40. PubMed ID: 8787235
    [No Abstract]   [Full Text] [Related]  

  • 25. Animal models of amyotrophic lateral sclerosis.
    Mitsumoto H; Pioro EP
    Adv Neurol; 1995; 68():73-87; discussion 89-91. PubMed ID: 8787246
    [No Abstract]   [Full Text] [Related]  

  • 26. Increased serum CNTF level in patients with amyotrophic lateral sclerosis.
    Iłzecka J
    Eur Cytokine Netw; 2003; 14(3):192-4. PubMed ID: 14656696
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Herpes labialis associated with recombinant human ciliary neurotrophic factor.
    Kriesel JD; Araneo B; Petajan JP; Spruance SL; Stromatt S
    J Infect Dis; 1994 Oct; 170(4):1046. PubMed ID: 7930707
    [No Abstract]   [Full Text] [Related]  

  • 28. Toxicity and tolerability of recombinant human ciliary neurotrophic factor in patients with amyotrophic lateral sclerosis.
    Miller RG; Bryan WW; Dietz MA; Munsat TL; Petajan JH; Smith SA; Goodpasture JC
    Neurology; 1996 Nov; 47(5):1329-31. PubMed ID: 8909453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Etiological drug therapy for amyotrophic lateral sclerosis].
    Cintas P
    Rev Neurol (Paris); 2006 Jun; 162 Spec No 2():4S220-4S227. PubMed ID: 17128115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stem cells: comprehensive treatments for amyotrophic lateral sclerosis in conjunction with growth factor delivery.
    Lunn JS; Hefferan MP; Marsala M; Feldman EL
    Growth Factors; 2009 Jun; 27(3):133-40. PubMed ID: 19294549
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Controversies about amyotrophic lateral sclerosis.
    Rowland LP
    Neurologia; 1996 Dec; 11 Suppl 5():72-4. PubMed ID: 9011143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Experimental models of amyotrophic lateral sclerosis].
    Galán L; Vela A; Guerrero A; Barcia JA; García-Verdugo JM; Matias-Guiu J
    Neurologia; 2007; 22(6):381-8. PubMed ID: 17610166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Gene therapy and neurotrophic factor treatment for amyotrophic lateral sclerosis].
    Abe K; Manabe Y; Murakami T
    Rinsho Shinkeigaku; 2001 Dec; 41(12):1160-1. PubMed ID: 12235826
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug therapy for amyotrophic lateral sclerosis: Where are we now?
    Carter GT; Krivickas LS; Weydt P; Weiss MD; Miller RG
    IDrugs; 2003 Feb; 6(2):147-53. PubMed ID: 12789618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Possible etiological role retroviruses and enteroviruses in the development of amyotrophic lateral sclerosis].
    Portegies P; Cohen ES
    Ned Tijdschr Geneeskd; 2002 Jul; 146(30):1398-400. PubMed ID: 12174431
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ciliary neurotropic factor in skin biopsies of patients with amyotrophic lateral sclerosis.
    Ono S; Imai T; Shimizu N; Nakagawa H; Hu J
    Lancet; 1998 Sep; 352(9132):958-9. PubMed ID: 9752822
    [No Abstract]   [Full Text] [Related]  

  • 37. Motor unit number estimates and quantitative muscle strength measurements of distal muscles in patients with amyotrophic lateral sclerosis.
    Armon C; Brandstater ME; Peterson GW
    Muscle Nerve; 1997 Apr; 20(4):499-501. PubMed ID: 9121509
    [No Abstract]   [Full Text] [Related]  

  • 38. Inflammatory processes in amyotrophic lateral sclerosis.
    McGeer PL; McGeer EG
    Muscle Nerve; 2002 Oct; 26(4):459-70. PubMed ID: 12362410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of amyotrophic lateral sclerosis - what is the next step?
    Ludolph AC
    J Neurol; 2000 Dec; 247 Suppl 6():VI/13-8. PubMed ID: 19714403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Encapsulated xenogeneic cells: delivering CNTF to motor neurons.
    O'Brien C
    Mol Med Today; 1996 Nov; 2(11):448-9. PubMed ID: 8947909
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.